Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10767118 | 0.80 | POLB (0.47) | CTSGCMA1ALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL6232185 | 0.78 | CTSG (0.44) | CTSGCMA1ALDH1A1KMT2APOLB | |
| SCHEMBL11279187 | 0.78 | PDE7A (0.45) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19KMT2A | |
| SCHEMBL3422430 | 0.76 | CYP2C9 (0.47) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19KMT2A | |
| SCHEMBL3420466 | 0.76 | CYP2C9 (0.47) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19KMT2A | |
| SCHEMBL14045645 | 0.74 | CYP2C9 (0.53) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19KMT2A | |
| SCHEMBL19923627 | 0.73 | CTSG (0.41) | CTSGCMA1ALDH1A1KMT2APOLB | |
| SCHEMBL11124350 | 0.72 | POLB (0.42) | CTSGCMA1ALDH1A1KMT2APOLB | |
| SCHEMBL11088410 | 0.71 | NPSR1 (0.50) | CTSGCMA1ALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL23900255 | 0.70 | OPRM1 (0.49) | ALDH1A1SMN1; SMN2CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| EP-3639821-B1 | CARCINOGENESIS INHIBITOR | NAT CANCER CT (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110740729-B | Carcinogenesis inhibitor | 国立研究开发法人国立癌症研究中心 | 2023-05-16 | — | — | CN | disclosed |
| US-11464762-B2 | Carcinogenesis inhibitor | NATIONAL CANCER CENTER (JP) | 2022-10-11 | — | — | US | disclosed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | NATIONAL CANCER CENTER (JP) | 2020-09-03 | — | — | US | disclosed |
| EP-3639821-A1 | CARCINOGENESIS INHIBITOR | National Cancer Center (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
| EP-1243261-B1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-27 | — | — | EP | disclosed |
| CN-1197572-C | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-20 | — | — | CN | disclosed |
| EP-1243261-A1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6451831-B1 | TREATMENT WITH HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| CN-1253775-A | Refractory vasculitis therapeutic preparation | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-05-24 | — | — | CN | disclosed |
| CN-1159324-A | Active oxygen, free radical scavenger | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | CN | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | CTSG 1654/4885CMA1 4120/4885ALDH1A1 2648/4885 |
| US-11464762-B2 | Carcinogenesis inhibitor | APC, MKI67, HRAS | CTSG 1560/4885CMA1 1051/4885ALDH1A1 759/4885 |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | APC, MKI67, HRAS | CTSG 1560/4885CMA1 1051/4885ALDH1A1 759/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | CTSG 1736/4885CMA1 3987/4885ALDH1A1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.